It is becoming clear that epigenetic changes are involved in cancer as much as in normal development. We recently identified RBP2, a protein interacting with the pRB tumor suppressor, which seems to mediate the pRB function in differentiation. RBP2 and the closely related protein PLU1 are two newly identified histone demethylases associated with malignancy. Their transcriptional regulation has been connected to the demethylation of trimethylated lysine 4 of histone H3 (H3K4me3). We recently identified differentiation- specific RBP2 targets genome-wide. We propose that RBP2 establishes, in a pRB dependent manner, a transcriptional program that regulates progression to a more differentiated state and may be a requisite component of leukemia and lymphoma development. In this application we will study how RBP2 is recruited to its genomic targets and which factors change the affinity or specificity of RBP2 binding. We suggest to use molecular, cell biological and genetic approaches to fulfill the following specific aims: (1) To determine the requirements of histone H3K4 methylation, sequence-specific DNA binding, the three PHD finger cassettes and E2F binding for RBP2 recruitment to genomic loci;(2) To dissect the RBP2 recruitment mechanisms that result in gene expression changes;(3) To determine RBP2 target gene expression in cancer cells deficient in RBP2 function compared with normal cells. This study will contribute to the development of therapeutic approaches involving this novel class of epigenetic regulators.

Public Health Relevance

Understanding RBP2 function could lead to tremendous impact on public health in several ways: 1) improve cost-efficiency of cancer screening programs adapted to individual's risk factors;2) identify individuals who will most benefit from a particular prevention strategy;3) lead to rational drug design of demethylase inhibitors, for example, bisubstrate analogues, to target wide range of cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA138631-04
Application #
8403875
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Mietz, Judy
Project Start
2010-01-01
Project End
2014-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
4
Fiscal Year
2013
Total Cost
$307,042
Indirect Cost
$107,843
Name
University of Illinois at Chicago
Department
Biochemistry
Type
Schools of Medicine
DUNS #
098987217
City
Chicago
State
IL
Country
United States
Zip Code
60612
Ambrus, Aaron M; Islam, Abul B M M K; Holmes, Katherine B et al. (2013) Loss of dE2F compromises mitochondrial function. Dev Cell 27:438-51
Jene-Sanz, Alba; Varaljai, Renata; Vilkova, Alexandra V et al. (2013) Expression of polycomb targets predicts breast cancer prognosis. Mol Cell Biol 33:3951-61
Islam, Abul B M M K; Richter, William F; Jacobs, Laura A et al. (2011) Co-regulation of histone-modifying enzymes in cancer. PLoS One 6:e24023
Islam, Abul B M M K; Richter, William F; Lopez-Bigas, Nuria et al. (2011) Selective targeting of histone methylation. Cell Cycle 10:413-24
Lin, Wenchu; Cao, Jian; Liu, Jiayun et al. (2011) Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci U S A 108:13379-86
Nicolay, Brandon N; Bayarmagnai, Battuya; Moon, Nam Sung et al. (2010) Combined inactivation of pRB and hippo pathways induces dedifferentiation in the Drosophila retina. PLoS Genet 6:e1000918
Beshiri, Michael L; Islam, Abul; DeWaal, Dannielle C et al. (2010) Genome-wide analysis using ChIP to identify isoform-specific gene targets. J Vis Exp :